TO6 - generating monoclonal cell lines, monoclonal antibodies, and labeled monoclonal antibodies against human and mouse colq
Ended Awarded Last action
- Contract number
- 75N95023F00001
- Awardee
-
A&G Pharmaceutical, Inc. UEI SN6SWFABJXL1
- Awarding agency
-
National Institute on Drug Abuse
National Institutes of Health, Department of Health and Human Services
- Obligated
- $132,863
Award facts
- Contract value 100% obligated
- $132,862.50 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Funding agency
- National Center for Advancing Translational Sciences National Institutes of Health, Department of Health and Human Services
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Basic Research
- Pricing
- Firm Fixed Price
- Place of performance
- Rockville, MD 20850, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | $16,463 | |
| Original award | $116,400 |
About this award
The Department of Health and Human Services' National Institutes of Health National Center for Advancing Translational Sciences awarded a $132,862.50 firm fixed price delivery order contract to A&G Pharmaceutical, Inc., doing business as Precision Antibody, to support the agency's research efforts. Under the contract, TO6 - GENERATING MONOCLONAL CELL LINES, MONOCLONAL ANTIBODIES, AND LABELED MONOCLONAL ANTIBODIES AGAINST HUMAN AND MOUSE COLQ, Precision Antibody will provide monoclonal cell lines, monoclonal antibodies, and labeled monoclonal antibodies against human and mouse collagen Q from August 31, 2023 through the completion date of August 31, 2024. As a manufacturer of goods and for-profit organization, Precision Antibody has extensive experience providing custom antibody development services to support biomedical research programs across the National Institutes of Health and other components of the Department of Health and Human Services.
Quick answers
Who was awarded contract 75N95023F00001?
75N95023F00001 was awarded to A&G Pharmaceutical, Inc. by National Institute on Drug Abuse (National Institutes of Health) on September 1, 2023.
How much is contract 75N95023F00001 worth?
The government has obligated $132,863 on 75N95023F00001.
Which agency awarded contract 75N95023F00001?
National Institute on Drug Abuse (National Institutes of Health) awarded 75N95023F00001, with funding from National Center for Advancing Translational Sciences (National Institutes of Health).
Is contract 75N95023F00001 an order under another contract?
Yes. 75N95023F00001 is a delivery order under 75N95018D00010, an indefinite delivery contract.
Was contract 75N95023F00001 competed?
The extent of competition for 75N95023F00001 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award